HK1070287A1 - Hepatitis c virus inhibitors - Google Patents
Hepatitis c virus inhibitorsInfo
- Publication number
- HK1070287A1 HK1070287A1 HK05103045.4A HK05103045A HK1070287A1 HK 1070287 A1 HK1070287 A1 HK 1070287A1 HK 05103045 A HK05103045 A HK 05103045A HK 1070287 A1 HK1070287 A1 HK 1070287A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hepatitis
- virus inhibitors
- virus
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38205502P | 2002-05-20 | 2002-05-20 | |
PCT/US2003/015755 WO2003099274A1 (en) | 2002-05-20 | 2003-05-20 | Hepatitis c virus inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1070287A1 true HK1070287A1 (en) | 2005-06-17 |
Family
ID=29584353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05103045.4A HK1070287A1 (en) | 2002-05-20 | 2005-04-11 | Hepatitis c virus inhibitors |
Country Status (34)
Country | Link |
---|---|
US (9) | US6995174B2 (pt) |
EP (2) | EP1505963B9 (pt) |
JP (1) | JP4312710B2 (pt) |
KR (2) | KR20100093140A (pt) |
CN (3) | CN1974596B (pt) |
AR (3) | AR040080A1 (pt) |
AT (1) | ATE506104T1 (pt) |
AU (1) | AU2003241510B2 (pt) |
BR (1) | BR0311132A (pt) |
CA (1) | CA2486308C (pt) |
CO (1) | CO5640083A2 (pt) |
CY (1) | CY1112108T1 (pt) |
DE (1) | DE60336807D1 (pt) |
DK (1) | DK1505963T3 (pt) |
ES (1) | ES2363131T3 (pt) |
GE (1) | GEP20063938B (pt) |
HK (1) | HK1070287A1 (pt) |
HR (1) | HRP20041085B1 (pt) |
IL (1) | IL164987A (pt) |
IS (1) | IS7530A (pt) |
MX (1) | MXPA04011440A (pt) |
MY (1) | MY140680A (pt) |
NO (1) | NO332427B1 (pt) |
NZ (1) | NZ536539A (pt) |
PE (1) | PE20040517A1 (pt) |
PL (1) | PL226561B1 (pt) |
PT (1) | PT1505963E (pt) |
RS (1) | RS52407B (pt) |
RU (3) | RU2298001C2 (pt) |
SI (1) | SI1505963T1 (pt) |
TW (1) | TWI306452B (pt) |
UA (1) | UA80973C2 (pt) |
WO (1) | WO2003099274A1 (pt) |
ZA (1) | ZA200409162B (pt) |
Families Citing this family (279)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20060199773A1 (en) * | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
JP4682140B2 (ja) * | 2003-03-05 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類縁体 |
WO2004101605A1 (en) * | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
ATE422895T1 (de) * | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
US7273851B2 (en) | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7135462B2 (en) * | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) * | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1730167B1 (en) | 2004-01-21 | 2011-01-12 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
SE0400199D0 (sv) * | 2004-01-30 | 2004-01-30 | Medivir Ab | HCV Protease inhbitors |
US7608590B2 (en) | 2004-01-30 | 2009-10-27 | Medivir Ab | HCV NS-3 serine protease inhibitors |
DK1718608T3 (da) | 2004-02-20 | 2013-10-14 | Boehringer Ingelheim Int | Virale polymeraseinhibitorer |
ATE459638T1 (de) * | 2004-03-15 | 2010-03-15 | Boehringer Ingelheim Int | Verfahren zur herstellung makrocyclischer dipeptide, die sich für die behandlung von hepatitis-c-virusinfektionen eignen |
AU2005228894B9 (en) * | 2004-03-30 | 2011-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
EP1753775B1 (en) | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
WO2006000085A1 (en) | 2004-06-28 | 2006-01-05 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
JP5049124B2 (ja) * | 2004-07-09 | 2012-10-17 | メディスィン テクノロジーズ, インコーポレイテッド | 治療化合物および処置 |
AU2005274700B2 (en) * | 2004-07-16 | 2011-11-10 | Gilead Sciences, Inc. | Antiviral compounds |
ES2366478T3 (es) * | 2004-07-20 | 2011-10-20 | Boehringer Ingelheim International Gmbh | Análogos peptídicos inhibidores de la hepatitis c. |
UY29016A1 (es) * | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
JP2008511633A (ja) * | 2004-08-27 | 2008-04-17 | シェーリング コーポレイション | C型肝炎ウィルスns3セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物 |
CN102796081B (zh) | 2004-08-28 | 2015-04-22 | 阿斯利康(瑞典)有限公司 | 作为趋化因子受体调节剂的嘧啶磺酰胺衍生物 |
WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7601686B2 (en) * | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
WO2007009227A1 (en) * | 2005-07-20 | 2007-01-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
PL1919898T3 (pl) | 2005-07-29 | 2011-06-30 | Tibotec Pharm Ltd | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
EP2314295B1 (en) | 2005-07-29 | 2015-01-28 | Resverlogix, Inc | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
EP1919899B1 (en) | 2005-07-29 | 2011-01-19 | Tibotec Pharmaceuticals | Macrocyclic inhibitors of hepatitis c virus |
CA2615896C (en) * | 2005-08-01 | 2012-11-13 | Merck & Co., Inc. | Macrocyclic peptides as hcv ns3 protease inhibitors |
CA2618682C (en) | 2005-08-12 | 2011-06-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
NZ568135A (en) | 2005-10-11 | 2011-06-30 | Array Biopharma Inc | Macrocyclic compounds and methods for inhibiting hepatitis C viral replication |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為p2x7調節劑之雙環雜芳基化合物與其用途 |
EP2007789B1 (en) * | 2006-04-11 | 2015-05-20 | Novartis AG | Spirocyclic HCV/HIV inhibitors and their uses |
GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US20080187516A1 (en) * | 2006-06-06 | 2008-08-07 | Ying Sun | Acyclic oximyl hepatitis c protease inhibitors |
US7728148B2 (en) * | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
UY30437A1 (es) * | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EA017448B1 (ru) | 2006-07-13 | 2012-12-28 | Ачиллион Фармасьютикалз, Инк. | 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации |
US20090035267A1 (en) * | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
US20080038225A1 (en) * | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
US20090098085A1 (en) * | 2006-08-11 | 2009-04-16 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
MX2009000882A (es) | 2006-08-17 | 2009-02-04 | Boehringer Ingelheim Int | Inhibidores de la polimerasa virica. |
AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
WO2008051475A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
EP2079480B1 (en) | 2006-10-24 | 2013-06-05 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
MX2009004556A (es) | 2006-10-27 | 2009-07-10 | Merck & Co Inc | Inhibidores de la proteasa ns3 del hcv. |
CA2667032A1 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US20080107623A1 (en) * | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
US20080107625A1 (en) * | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
WO2008057995A2 (en) * | 2006-11-02 | 2008-05-15 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
US9828597B2 (en) | 2006-11-22 | 2017-11-28 | Toyota Motor Engineering & Manufacturing North America, Inc. | Biofunctional materials |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
WO2008075103A1 (en) | 2006-12-20 | 2008-06-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US20080161254A1 (en) * | 2007-01-03 | 2008-07-03 | Virobay, Inc. | Hcv inhibitors |
MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
US20080207528A1 (en) * | 2007-02-01 | 2008-08-28 | Syaulan Yang | Hcv protease inhibitors |
EP2118091B1 (en) | 2007-02-08 | 2015-04-15 | Janssen Sciences Ireland UC | Pyrimidine substituted macrocyclic hcv inhibitors |
US8435984B2 (en) * | 2007-02-26 | 2013-05-07 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of HCV replication |
US8377872B2 (en) | 2007-04-26 | 2013-02-19 | Enanta Pharmaceuticals, Inc. | Cyclic P3 tripeptide hepatitis C serine protease inhibitors |
US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
US20080317712A1 (en) * | 2007-04-26 | 2008-12-25 | Deqiang Niu | Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors |
US20080292587A1 (en) * | 2007-04-26 | 2008-11-27 | Ying Sun | Oximyl dipeptide hepatitis c protease inhibitors |
US7910587B2 (en) * | 2007-04-26 | 2011-03-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl dipeptide hepatitis C virus inhibitors |
NZ581606A (en) * | 2007-05-03 | 2012-06-29 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
AP2009005057A0 (en) * | 2007-05-10 | 2009-12-31 | Array Biopharma Inc | Novel peptide inhibitors of hepatitis c virus replication |
US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
AP2009005073A0 (en) | 2007-06-29 | 2009-12-31 | Gilead Sciences Inc | Antiviral compounds |
WO2009005690A2 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
MX2009013827A (es) * | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Compuestos antivirales. |
CA2693533A1 (en) | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
JP2010540549A (ja) * | 2007-09-24 | 2010-12-24 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ウイルス複製阻害剤としての尿素含有ペプチド |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
WO2009055335A2 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
EP2219454A4 (en) | 2007-11-14 | 2012-05-30 | Enanta Pharm Inc | HEMMER OF MACROCYCLIC TETRAZOLYL HEPATITIS C SERIN PROTEASE |
WO2009070689A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
WO2009070692A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
MX2010006210A (es) * | 2007-12-05 | 2010-08-10 | Enanta Pharm Inc | Inhibidores de serina proteasa de hcv de tripeptido fluorado. |
CA2708042A1 (en) | 2007-12-05 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl derivatives |
WO2009076166A2 (en) * | 2007-12-05 | 2009-06-18 | Enanta Pharmaceuticals, Inc. | Oximyl hcv serine protease inhibitors |
CA2709089A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Macrocyclic oximyl hepatitis c serine protease inhibitors |
WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
NZ585370A (en) | 2007-12-19 | 2012-09-28 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
AU2013231052B2 (en) * | 2007-12-21 | 2015-09-10 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Crystalline forms of n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-l-prolinamide |
US8202996B2 (en) * | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
CA2710144A1 (en) * | 2007-12-21 | 2009-07-02 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
NZ586231A (en) * | 2007-12-21 | 2012-12-21 | Avila Therapeutics Inc | HCV protease inhibitors comprising a functionalised proline derivative |
CN102036966A (zh) * | 2008-01-24 | 2011-04-27 | 益安药业 | 作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽 |
CN101980719A (zh) * | 2008-01-24 | 2011-02-23 | 益安药业 | 含杂芳基的三肽hcv丝氨酸蛋白酶抑制剂 |
AR070413A1 (es) * | 2008-02-04 | 2010-04-07 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de proteasa de serina |
MX2010010276A (es) | 2008-03-20 | 2011-03-25 | Enanta Pharm Inc | Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c. |
EA201071034A1 (ru) * | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009134624A1 (en) | 2008-04-28 | 2009-11-05 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US20090285773A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20090285774A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN101580535B (zh) * | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | 丙型肝炎病毒蛋白酶抑制剂 |
JP5529120B2 (ja) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルス阻害剤 |
US7964560B2 (en) * | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
ES2458358T3 (es) | 2008-07-02 | 2014-05-05 | Idenix Pharmaceuticals, Inc. | Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas |
ES2392611T3 (es) | 2008-07-22 | 2012-12-12 | Merck Sharp & Dohme Corp. | Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
CN102123994B (zh) * | 2008-08-29 | 2014-09-24 | Jsr株式会社 | N-羧基氨基酸酐和氨基酸氨基甲酸酯化合物的制造方法 |
US8207341B2 (en) * | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100080770A1 (en) * | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8383094B2 (en) * | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100272674A1 (en) * | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
PL2364309T3 (pl) * | 2008-12-10 | 2015-03-31 | Achillion Pharmaceuticals Inc | Nowe peptydy 4-amino-4-oksobutanoilowe jako inhibitory wirusowej replikacji |
CN102245598B (zh) * | 2008-12-10 | 2014-01-29 | 艾其林医药公司 | 病毒复制抑制剂4-氨基-4-氧代丁酰基肽环状类似物 |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AR074670A1 (es) | 2008-12-19 | 2011-02-02 | Gilead Sciences Inc | Inhibidores de la proteasa ns3 del vhc virus de la hepatitis c |
CA2746834A1 (en) | 2008-12-22 | 2010-07-01 | Gilead Sciences, Inc. | Antiviral compounds |
AU2010203656A1 (en) | 2009-01-07 | 2011-07-21 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of HCV and HIV infection |
CA2747417C (en) | 2009-01-08 | 2017-01-03 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
CA2751892A1 (en) | 2009-01-15 | 2010-07-22 | Rutgers, The State University Of New Jersey | Benzo [c] phenanthridines as antimicrobial agents |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
US8193372B2 (en) | 2009-03-04 | 2012-06-05 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole HCV polymerase inhibitors |
US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2758072A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
BRPI1014956B8 (pt) | 2009-04-22 | 2021-05-25 | Resverlogix Corp | agentes anti-inflamatórios |
WO2010127307A1 (en) | 2009-04-30 | 2010-11-04 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
MX2011012155A (es) | 2009-05-13 | 2012-02-28 | Enanta Pharm Inc | Compuestos macrociclicos como inhibidores del virus de hepatitis c. |
US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
EP2459582B1 (en) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
LT2477980T (lt) | 2009-09-15 | 2016-09-26 | Taigen Biotechnology Co., Ltd. | Hcv proteazės slopikliai |
WO2011038293A1 (en) * | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
US9193740B2 (en) * | 2009-10-19 | 2015-11-24 | Enanta Pharmaceuticals, Inc. | Bismacrocyclic compounds as hepatitis C virus inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2784748A1 (en) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
WO2011123586A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
CA2810162A1 (en) | 2010-06-09 | 2011-12-15 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
US10988714B2 (en) | 2010-06-21 | 2021-04-27 | Regents Of The University Of Minnesota | Methods of facilitating removal of a fingerprint from a substrate or a coating |
US9388370B2 (en) * | 2010-06-21 | 2016-07-12 | Toyota Motor Engineering & Manufacturing North America, Inc. | Thermolysin-like protease for cleaning insect body stains |
US11015149B2 (en) | 2010-06-21 | 2021-05-25 | Toyota Motor Corporation | Methods of facilitating removal of a fingerprint |
US8796009B2 (en) | 2010-06-21 | 2014-08-05 | Toyota Motor Engineering & Manufacturing North America, Inc. | Clearcoat containing thermolysin-like protease from Bacillus stearothermophilus for cleaning of insect body stains |
US9121016B2 (en) | 2011-09-09 | 2015-09-01 | Toyota Motor Engineering & Manufacturing North America, Inc. | Coatings containing polymer modified enzyme for stable self-cleaning of organic stains |
US9102617B2 (en) | 2010-06-25 | 2015-08-11 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
US20120196794A1 (en) * | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
SI2618831T1 (sl) | 2010-09-21 | 2016-06-30 | Enanta Pharmaceuticals, Inc. | Makrociklični inhibitorji proteaze HCV na osnovi prolina |
JP5619289B2 (ja) | 2010-09-24 | 2014-11-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
BR112013010836A2 (pt) | 2010-11-01 | 2019-09-24 | Genoscience Pharma | inibidores específicos de ns3 protease de hcv |
US9120818B2 (en) | 2010-12-14 | 2015-09-01 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
US9173887B2 (en) | 2010-12-22 | 2015-11-03 | Abbvie Inc. | Hepatitis C inhibitors and uses thereof |
EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途 |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
JP6110846B2 (ja) * | 2011-05-27 | 2017-04-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド |
RS55123B1 (sr) * | 2011-05-27 | 2016-12-30 | Achillion Pharmaceuticals Inc | Supstituisani alifani, ciklofani, heterafani, heterofani, hetero-heterafani i metaloceni korisni za lečenje infekcija hepatitis c virusa |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102911254A (zh) * | 2011-08-02 | 2013-02-06 | 上海唐润医药科技有限公司 | Hcv蛋白酶抑制剂 |
AU2012308900A1 (en) | 2011-09-12 | 2013-05-09 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物 |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
CN104383541A (zh) | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
SE1450131A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV |
JP5992049B2 (ja) | 2011-11-01 | 2016-09-14 | レスバーロジックス コーポレイション | 置換されたキナゾリノンのための経口速放性製剤 |
US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
CA2863002A1 (en) | 2012-01-11 | 2013-07-18 | Abbvie Inc. | Processes for making hcv protease inhibitors |
CA2858814A1 (en) * | 2012-01-12 | 2013-07-18 | Rfs Pharma, Llc | Hcv ns3 protease inhibitors |
US9822108B2 (en) | 2012-01-13 | 2017-11-21 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
WO2013132253A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
WO2013142712A1 (en) | 2012-03-21 | 2013-09-26 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
WO2013169577A1 (en) | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
US20130302414A1 (en) | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
EP2852603B1 (en) | 2012-05-22 | 2021-05-12 | Idenix Pharmaceuticals LLC | D-amino acid compounds for liver disease |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
US9376433B2 (en) * | 2012-08-08 | 2016-06-28 | Merck Patent Gmbh | (AZA-)isoquinolinone derivatives |
CN111848711A (zh) | 2012-10-08 | 2020-10-30 | 埃迪尼克斯医药有限责任公司 | 用于hcv感染的2′-氯核苷类似物 |
BR112015007879A2 (pt) | 2012-10-19 | 2017-07-04 | Bristol Myers Squibb Co | inibidores do vírus da hepatite c |
WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US20140140951A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Rp-Nucleoside Analog |
CN103804208B (zh) * | 2012-11-14 | 2016-06-08 | 重庆博腾制药科技股份有限公司 | 一种丙肝药物中间体的制备方法 |
WO2014078436A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
JP2016515139A (ja) | 2013-03-14 | 2016-05-26 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ソバプレビルの新規の製造方法 |
BR112015023351A2 (pt) | 2013-03-15 | 2017-07-18 | Achillion Pharmaceuticals Inc | forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio |
WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
AU2014320149A1 (en) | 2013-09-11 | 2016-04-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
EP3063165A1 (en) | 2013-11-01 | 2016-09-07 | Idenix Pharmaceuticals LLC | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
US9458150B2 (en) | 2013-11-08 | 2016-10-04 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
EP3083654A1 (en) | 2013-12-18 | 2016-10-26 | Idenix Pharmaceuticals LLC | 4'-or nucleosides for the treatment of hcv |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
EP3113763A1 (en) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
CN106459145A (zh) | 2014-06-25 | 2017-02-22 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
JP6903585B2 (ja) | 2015-03-13 | 2021-07-14 | レスバーロジックス コーポレイション | 補体関連疾患の治療のための組成物および治療方法 |
JP6740354B2 (ja) | 2015-10-05 | 2020-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | オートファジーの流れ及びホスホリパーゼd及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 |
US10513528B2 (en) | 2016-02-25 | 2019-12-24 | Taxis Pharmaceuticals, Inc. | Synthetic processes and intermediates |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
CN107641099A (zh) * | 2016-07-20 | 2018-01-30 | 广东东阳光药业有限公司 | 取代的4‑羟基喹啉类化合物的制备方法 |
US9957233B1 (en) | 2016-08-05 | 2018-05-01 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
CN110891566B (zh) | 2017-03-30 | 2023-12-19 | 塔克西斯医药股份有限公司 | 合成方法和合成中间体 |
WO2018236928A1 (en) * | 2017-06-20 | 2018-12-27 | University Of Massachusetts | NS3 / 4A PROTEASE INHIBITORS OF HEPATITIS C VIRUS |
CN110156684A (zh) * | 2019-06-28 | 2019-08-23 | 珠海市柏瑞医药科技有限公司 | 一种去甲乌药碱及其药用盐的合成工艺 |
US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
CN113402450B (zh) * | 2021-01-13 | 2023-11-24 | 上海睿腾医药科技有限公司 | 一种2-溴-4-氯吡啶的纯化方法 |
US20240101531A1 (en) | 2022-06-08 | 2024-03-28 | Xenon Pharmaceuticals Inc. | Pyridinamine derivatives and their use as potassium channel modulators |
Family Cites Families (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US185001A (en) | 1876-12-05 | Improvement in measuring-faucets | ||
JPS57123181A (en) | 1981-01-23 | 1982-07-31 | Mitsubishi Paper Mills Ltd | Preparation of pyrazolo (1,5-a) pyridine derivative |
EP0475255A3 (en) | 1990-09-12 | 1993-04-14 | F. Hoffmann-La Roche Ag | Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid |
US5610054A (en) * | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US5500208A (en) | 1994-06-07 | 1996-03-19 | The Procter & Gamble Company | Oral compositions comprising a novel tripeptide |
MY147327A (en) * | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
US5633388A (en) * | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
JPH11513890A (ja) | 1996-05-10 | 1999-11-30 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼの合成インヒビター |
CA2268391A1 (en) * | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) * | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
YU34599A (sh) * | 1997-01-23 | 2002-03-18 | F. Hoffmann-La Roche Ag. | Inhibitori sulfamid-metaloproteaze |
WO1998046597A1 (en) | 1997-04-14 | 1998-10-22 | Emory University | Serine protease inhibitors |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
ES2234144T3 (es) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | Analogos de peptidos inhibidores de la hepatitis c. |
HUP0004853A3 (en) | 1997-08-11 | 2001-12-28 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptides, process for preparation thereof, pharmaceutical compositions comprising thereof, their use and their intermediates |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
JP4690545B2 (ja) | 1998-03-31 | 2011-06-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
ES2244204T3 (es) | 1998-07-27 | 2005-12-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Derivados de dicetoacidos como inhibidores de polimerasas. |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
CN1325309A (zh) | 1998-08-21 | 2001-12-05 | 维洛药品公司 | 用于治疗或预防病毒感染和相关疾病的化合物、组合物和方法 |
CA2343522A1 (en) | 1998-09-04 | 2000-03-16 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
AU751457B2 (en) | 1998-09-25 | 2002-08-15 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
CN1167680C (zh) | 1999-12-27 | 2004-09-22 | 日本烟草产业株式会社 | 稠环化合物及其药物用途 |
WO2001085172A1 (en) | 2000-05-10 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
WO2002000808A1 (en) | 2000-06-23 | 2002-01-03 | General Electric Company | Silicone pressure sensitive adhesive composition |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
IL153670A0 (en) | 2000-07-21 | 2003-07-06 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
AU2002248147B2 (en) | 2000-11-20 | 2006-04-06 | Bristol-Myers Squibb Company | Hepatitis C tripeptide inhibitors |
JP2004525150A (ja) | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
ES2350201T3 (es) * | 2002-05-20 | 2011-01-20 | Bristol-Myers Squibb Company | Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c. |
JP4271148B2 (ja) | 2002-05-20 | 2009-06-03 | ブリストル−マイヤーズ スクイブ カンパニー | 置換シクロアルキルp1’c型肝炎ウイルスインヒビター |
US20060199773A1 (en) * | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ATE503764T1 (de) | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
HN2003000348A (es) | 2002-11-01 | 2008-10-14 | Viropharma Inc | Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas. |
US7601709B2 (en) * | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
CN1771050A (zh) | 2003-02-07 | 2006-05-10 | 益安药业 | 丙型肝炎丝氨酸蛋白酶的大环抑制剂 |
JP4682140B2 (ja) | 2003-03-05 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類縁体 |
WO2004101605A1 (en) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
CN100363055C (zh) | 2003-04-02 | 2008-01-23 | 贝林格尔·英格海姆国际有限公司 | 用作c型肝炎病毒蛋白酶抑制剂的药物组合物 |
ATE422895T1 (de) | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
ES2335887T3 (es) | 2003-04-18 | 2010-04-06 | Enanta Pharmaceuticals, Inc. | Compuestos macrociclicos de quinoxalinilo que inhiben las serina proteasas de la hepatitis c. |
AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
US7642235B2 (en) | 2003-09-22 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
RU2006115558A (ru) | 2003-10-10 | 2007-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы |
CA2540858C (en) | 2003-10-14 | 2009-12-08 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7135462B2 (en) * | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2007532479A (ja) | 2003-11-20 | 2007-11-15 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼの脱ペプチド化インヒビター |
US7309708B2 (en) * | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1730167B1 (en) | 2004-01-21 | 2011-01-12 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
US7608590B2 (en) | 2004-01-30 | 2009-10-27 | Medivir Ab | HCV NS-3 serine protease inhibitors |
ATE459638T1 (de) | 2004-03-15 | 2010-03-15 | Boehringer Ingelheim Int | Verfahren zur herstellung makrocyclischer dipeptide, die sich für die behandlung von hepatitis-c-virusinfektionen eignen |
AU2005228894B9 (en) | 2004-03-30 | 2011-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
WO2006016930A2 (en) | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
EP1753775B1 (en) | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
WO2006000085A1 (en) | 2004-06-28 | 2006-01-05 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
AU2005274700B2 (en) | 2004-07-16 | 2011-11-10 | Gilead Sciences, Inc. | Antiviral compounds |
ES2366478T3 (es) | 2004-07-20 | 2011-10-20 | Boehringer Ingelheim International Gmbh | Análogos peptídicos inhibidores de la hepatitis c. |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
JP2008511633A (ja) | 2004-08-27 | 2008-04-17 | シェーリング コーポレイション | C型肝炎ウィルスns3セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物 |
EP1794178A1 (en) | 2004-09-17 | 2007-06-13 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
WO2006043145A1 (en) | 2004-10-21 | 2006-04-27 | Pfizer Inc. | Inhibitors of hepatitis c virus protease, and compositions and treatments using the same |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1863833B1 (en) | 2005-03-08 | 2013-09-18 | Boehringer Ingelheim International GmbH | Process for preparing macrocyclic compounds |
CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2006130688A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Compounds for inhibiting cathepsin activity |
EP1891089B1 (en) | 2005-06-02 | 2014-11-05 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
WO2006130627A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis c |
US20070004635A1 (en) | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
WO2006130626A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
EP1919478B1 (en) | 2005-06-02 | 2016-03-23 | Merck Sharp & Dohme Corp. | Combination of hcv protease inhibitors with a surfactant |
US20060276406A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
NZ563369A (en) | 2005-06-02 | 2011-03-31 | Schering Corp | Controlled-release formulation useful for treating disorders associated with hepatitus C virus |
WO2006130666A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
US20070021351A1 (en) | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
US20060276407A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW200738742A (en) | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
WO2007009227A1 (en) | 2005-07-20 | 2007-01-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
EP1919899B1 (en) | 2005-07-29 | 2011-01-19 | Tibotec Pharmaceuticals | Macrocyclic inhibitors of hepatitis c virus |
US8012939B2 (en) | 2005-07-29 | 2011-09-06 | Tibotec Pharmaceuticals Ltd. Co | Macrocyclic inhibitors of hepatitis C virus |
PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
PL1919898T3 (pl) | 2005-07-29 | 2011-06-30 | Tibotec Pharm Ltd | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
BRPI0614637A2 (pt) | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | inibidores macrocìclicos do vìrus da hepatite c |
CN101273038A (zh) | 2005-07-29 | 2008-09-24 | 美迪维尔公司 | 丙型肝炎病毒的大环化合物抑制剂 |
RU2441870C2 (ru) | 2005-07-29 | 2012-02-10 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
MY142972A (en) | 2005-07-29 | 2011-01-31 | Tibotec Pharm Ltd | Macrocyclic inhibitors of hepatitis c virus |
JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
CA2615896C (en) | 2005-08-01 | 2012-11-13 | Merck & Co., Inc. | Macrocyclic peptides as hcv ns3 protease inhibitors |
WO2007016476A2 (en) | 2005-08-01 | 2007-02-08 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
NZ568135A (en) | 2005-10-11 | 2011-06-30 | Array Biopharma Inc | Macrocyclic compounds and methods for inhibiting hepatitis C viral replication |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20070161670A1 (en) | 2006-01-09 | 2007-07-12 | Bristol-Myers Squibb Company | Process for the preparation of substituted heterocycles |
CA2644389A1 (en) | 2006-03-03 | 2007-09-20 | Schering Corporation | Pharmaceutical combinations of hcv-protease and -ires inhibitors |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US20070281884A1 (en) | 2006-06-06 | 2007-12-06 | Ying Sun | Macrocyclic oximyl hepatitis C protease inhibitors |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
UY30437A1 (es) | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EA017448B1 (ru) | 2006-07-13 | 2012-12-28 | Ачиллион Фармасьютикалз, Инк. | 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации |
US20090035267A1 (en) | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
WO2008019303A2 (en) | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors |
US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
CN101674844A (zh) | 2006-08-04 | 2010-03-17 | 英安塔制药有限公司 | 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂 |
US20090035268A1 (en) | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
US7605126B2 (en) | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
WO2008021960A2 (en) | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis c serine protease inhibitors |
US20080038225A1 (en) | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
WO2008022006A2 (en) | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
US7582605B2 (en) | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
WO2008051475A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
EP2079480B1 (en) | 2006-10-24 | 2013-06-05 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
CA2667032A1 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
MX2009004556A (es) | 2006-10-27 | 2009-07-10 | Merck & Co Inc | Inhibidores de la proteasa ns3 del hcv. |
US20080107623A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US20080107625A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
WO2008057995A2 (en) | 2006-11-02 | 2008-05-15 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008070358A2 (en) | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2010510192A (ja) | 2006-11-17 | 2010-04-02 | テイボテク・フアーマシユーチカルズ・リミテツド | C型肝炎ウイルスの大環状阻害剤 |
TWI455936B (zh) | 2007-02-01 | 2014-10-11 | Tibotec Pharm Ltd | 用於製備hcv之大環蛋白酶抑制劑之方法及中間物 |
US20080207528A1 (en) | 2007-02-01 | 2008-08-28 | Syaulan Yang | Hcv protease inhibitors |
JP5523110B2 (ja) | 2007-02-01 | 2014-06-18 | ヤンセン・アールアンドデイ・アイルランド | Hcvの大員環状阻害剤の多形形態 |
EP2118091B1 (en) | 2007-02-08 | 2015-04-15 | Janssen Sciences Ireland UC | Pyrimidine substituted macrocyclic hcv inhibitors |
KR20090111326A (ko) | 2007-02-08 | 2009-10-26 | 티보텍 파마슈티칼즈 리미티드 | Hcv 억제 마크로사이클릭 페닐카바메이트 |
WO2008096002A1 (en) | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
EP2125870A4 (en) | 2007-02-16 | 2011-04-06 | Boehringer Ingelheim Int | INHIBITORS OF NS3 PROTEASE OF HEPATITIS C |
KR20090111353A (ko) | 2007-02-20 | 2009-10-26 | 노파르티스 아게 | Hcv ns3 프로테아제 억제제로서 매크로시클릭 화합물 |
US8435984B2 (en) | 2007-02-26 | 2013-05-07 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of HCV replication |
KR101467598B1 (ko) | 2007-04-24 | 2014-12-01 | 에프. 호프만-라 로슈 아게 | Hcv 프로테아제 억제제 중간체의 제조방법 |
US20080287449A1 (en) | 2007-04-26 | 2008-11-20 | Deqiang Niu | Aza-tripeptide hepatitis c serine protease inhibitors |
US20080279821A1 (en) | 2007-04-26 | 2008-11-13 | Deqiang Niu | Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors |
US20080274080A1 (en) | 2007-04-26 | 2008-11-06 | Yat Sun Or | Aza-peptide macrocyclic hepatitis c serine protease inhibitors |
US20080292587A1 (en) | 2007-04-26 | 2008-11-27 | Ying Sun | Oximyl dipeptide hepatitis c protease inhibitors |
NZ581606A (en) | 2007-05-03 | 2012-06-29 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
AP2009005057A0 (en) | 2007-05-10 | 2009-12-31 | Array Biopharma Inc | Novel peptide inhibitors of hepatitis c virus replication |
AP2009005073A0 (en) | 2007-06-29 | 2009-12-31 | Gilead Sciences Inc | Antiviral compounds |
MX2009013827A (es) * | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Compuestos antivirales. |
AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
WO2009014730A1 (en) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US8202996B2 (en) * | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
AR070413A1 (es) * | 2008-02-04 | 2010-04-07 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de proteasa de serina |
US8163921B2 (en) * | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2392611T3 (es) * | 2008-07-22 | 2012-12-12 | Merck Sharp & Dohme Corp. | Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC |
US8207341B2 (en) * | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
-
2003
- 2003-05-19 MY MYPI20031846A patent/MY140680A/en unknown
- 2003-05-20 AT AT03731248T patent/ATE506104T1/de active
- 2003-05-20 CN CN2006101685139A patent/CN1974596B/zh not_active Expired - Fee Related
- 2003-05-20 WO PCT/US2003/015755 patent/WO2003099274A1/en active Application Filing
- 2003-05-20 CA CA2486308A patent/CA2486308C/en not_active Expired - Fee Related
- 2003-05-20 PL PL373411A patent/PL226561B1/pl unknown
- 2003-05-20 DE DE60336807T patent/DE60336807D1/de not_active Expired - Lifetime
- 2003-05-20 CN CNB03817068XA patent/CN1299677C/zh not_active Expired - Fee Related
- 2003-05-20 CN CN2006101689642A patent/CN101024671B/zh not_active Expired - Fee Related
- 2003-05-20 AU AU2003241510A patent/AU2003241510B2/en not_active Ceased
- 2003-05-20 NZ NZ536539A patent/NZ536539A/en not_active IP Right Cessation
- 2003-05-20 EP EP03731248A patent/EP1505963B9/en not_active Expired - Lifetime
- 2003-05-20 RU RU2004137480/04A patent/RU2298001C2/ru active
- 2003-05-20 AR ARP030101746A patent/AR040080A1/es active IP Right Grant
- 2003-05-20 KR KR1020107017350A patent/KR20100093140A/ko not_active Application Discontinuation
- 2003-05-20 ES ES03731248T patent/ES2363131T3/es not_active Expired - Lifetime
- 2003-05-20 RS YU100504A patent/RS52407B/en unknown
- 2003-05-20 RU RU2006134703/04A patent/RU2317303C1/ru active
- 2003-05-20 BR BR0311132-6A patent/BR0311132A/pt not_active Application Discontinuation
- 2003-05-20 UA UA20041210414A patent/UA80973C2/uk unknown
- 2003-05-20 RU RU2006134702/04A patent/RU2315039C9/ru active
- 2003-05-20 US US10/441,657 patent/US6995174B2/en not_active Expired - Lifetime
- 2003-05-20 DK DK03731248.5T patent/DK1505963T3/da active
- 2003-05-20 TW TW092113612A patent/TWI306452B/zh not_active IP Right Cessation
- 2003-05-20 PE PE2003000492A patent/PE20040517A1/es active IP Right Grant
- 2003-05-20 PT PT03731248T patent/PT1505963E/pt unknown
- 2003-05-20 MX MXPA04011440A patent/MXPA04011440A/es active IP Right Grant
- 2003-05-20 JP JP2004506798A patent/JP4312710B2/ja not_active Expired - Fee Related
- 2003-05-20 EP EP11163004A patent/EP2340830A3/en not_active Withdrawn
- 2003-05-20 GE GEAP8538A patent/GEP20063938B/en unknown
- 2003-05-20 KR KR1020047018702A patent/KR101005958B1/ko active Protection Beyond IP Right Term
- 2003-05-20 SI SI200332008T patent/SI1505963T1/sl unknown
-
2004
- 2004-11-02 IL IL164987A patent/IL164987A/en active Protection Beyond IP Right Term
- 2004-11-04 NO NO20044807A patent/NO332427B1/no not_active IP Right Cessation
- 2004-11-11 ZA ZA200409162A patent/ZA200409162B/en unknown
- 2004-11-16 IS IS7530A patent/IS7530A/is unknown
- 2004-11-18 HR HRP20041085AA patent/HRP20041085B1/hr not_active IP Right Cessation
- 2004-11-19 CO CO04116551A patent/CO5640083A2/es active IP Right Grant
-
2005
- 2005-04-11 HK HK05103045.4A patent/HK1070287A1/xx not_active IP Right Cessation
- 2005-12-07 US US11/295,914 patent/US7449479B2/en not_active Expired - Fee Related
-
2008
- 2008-09-02 US US12/202,603 patent/US7915291B2/en not_active Expired - Fee Related
-
2010
- 2010-12-13 US US12/966,175 patent/US8299094B2/en not_active Expired - Fee Related
-
2011
- 2011-07-15 CY CY20111100690T patent/CY1112108T1/el unknown
-
2012
- 2012-07-04 AR ARP120102417A patent/AR087051A2/es not_active Application Discontinuation
- 2012-08-29 US US13/597,381 patent/US8507722B2/en not_active Expired - Fee Related
-
2013
- 2013-04-11 AR ARP130101165A patent/AR090649A2/es active IP Right Grant
- 2013-05-24 US US13/901,637 patent/US8710229B2/en not_active Expired - Fee Related
-
2014
- 2014-02-18 US US14/183,247 patent/US8889871B2/en not_active Expired - Fee Related
- 2014-09-04 US US14/477,594 patent/US9227940B2/en not_active Expired - Fee Related
-
2015
- 2015-11-09 US US14/936,419 patent/US9636375B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1070287A1 (en) | Hepatitis c virus inhibitors | |
EP1684787A4 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
EP1684745A4 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
SI1414797T1 (sl) | Inhibitorji polimeraze virusa hepatitisa c, ki imajo heterobicikliäśno struktuo | |
HK1078870A1 (en) | Heterocyclic tripeptides as hepatitis c inhibitors | |
IL162673A0 (en) | Pharmaceutical compositions for hepatitis c viral protease inhibitors | |
EG25482A (en) | Inhibitors | |
EP1771453A4 (en) | DIPEPTIDE ANALOGUE AS HEPATITIS C HEMMER | |
AU2003206862A8 (en) | Hepatitis b vaccines | |
EP1532133A4 (en) | NF-: B INHIBITORS | |
PL376967A1 (pl) | Szczepionka przeciw HCV | |
AU2003294757A8 (en) | Formulations useful against hepatitis c virus infections | |
AU2003256404A8 (en) | Hepatitis c virus assays | |
AU2003230790A1 (en) | Hepatitis c virus sub-genomic replicons | |
AU2003266243A8 (en) | 1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors | |
GB2393570B (en) | Magnetrons | |
AU2003225479A1 (en) | Reporter-selectable hepatitis c virus replicon | |
AU2006233207A1 (en) | Hepatitis C virus inhibitors | |
GB0308941D0 (en) | Shellfish trap | |
EP1607101A4 (en) | INHIBITOR OF DEGRADATION OF PROTEIN INTERACTING WITH HEPATITIS B VIRUS PROTEIN X | |
AU2003263028A1 (en) | Mouse hepatitis virus detection | |
GB0313251D0 (en) | Viral inhibitors | |
SI1654261T1 (sl) | Inhibitorske spojine hepatitisa C | |
GB0229200D0 (en) | Hepatitis B vaccines | |
AU2002351795A1 (en) | Hepatitis x virus antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220520 |